[go: up one dir, main page]

WO2020139238A3 - Combinaisons pharmaceutiques comprenant du fingolimod et un spasmolytique - Google Patents

Combinaisons pharmaceutiques comprenant du fingolimod et un spasmolytique Download PDF

Info

Publication number
WO2020139238A3
WO2020139238A3 PCT/TR2019/051008 TR2019051008W WO2020139238A3 WO 2020139238 A3 WO2020139238 A3 WO 2020139238A3 TR 2019051008 W TR2019051008 W TR 2019051008W WO 2020139238 A3 WO2020139238 A3 WO 2020139238A3
Authority
WO
WIPO (PCT)
Prior art keywords
fingolimod
spasmolytic
pharmaceutical combinations
pharmaceutical
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2019/051008
Other languages
English (en)
Other versions
WO2020139238A2 (fr
Inventor
Melda MISIRLI
Nur PEHLIVAN AKALIN
Muge ULUSOY BOZYEL
Seyhan TURKKAN
Yavuz Dedeoglu
Burce CIFCI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Priority to EP19904739.0A priority Critical patent/EP3902531A4/fr
Publication of WO2020139238A2 publication Critical patent/WO2020139238A2/fr
Publication of WO2020139238A3 publication Critical patent/WO2020139238A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des combinaisons pharmaceutiques comprenant du fingolimod ou un sel pharmaceutiquement acceptable de celui-ci et au moins un spasmolytique.
PCT/TR2019/051008 2018-12-28 2019-11-28 Combinaisons pharmaceutiques comprenant du fingolimod et un spasmolytique Ceased WO2020139238A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19904739.0A EP3902531A4 (fr) 2018-12-28 2019-11-28 Combinaisons pharmaceutiques comprenant du fingolimod et un spasmolytique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2018/20976 2018-12-28
TR2018/20976A TR201820976A2 (tr) 2018-12-28 2018-12-28 Fi̇ngoli̇mod ve bi̇r spazmoli̇ti̇k i̇çeren farmasöti̇k kombi̇nasyonlar

Publications (2)

Publication Number Publication Date
WO2020139238A2 WO2020139238A2 (fr) 2020-07-02
WO2020139238A3 true WO2020139238A3 (fr) 2020-07-30

Family

ID=71130184

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/051008 Ceased WO2020139238A2 (fr) 2018-12-28 2019-11-28 Combinaisons pharmaceutiques comprenant du fingolimod et un spasmolytique

Country Status (3)

Country Link
EP (1) EP3902531A4 (fr)
TR (1) TR201820976A2 (fr)
WO (1) WO2020139238A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073510A1 (fr) * 2014-11-04 2016-05-12 Adamas Pharmaceuticals, Inc. Méthodes d'administration de compositions d'amantadine
WO2018082814A1 (fr) * 2016-11-07 2018-05-11 Metriopharm Ag Utilisation de 5-amino-2,3-dihydro-1,4-phthalazinedione dans le traitement de la sclérose en plaques progressive chronique
EP3398595A1 (fr) * 2012-08-03 2018-11-07 Fwp Ip Aps Polythérapie pour le traitement de la sclérose en plaques
TR201720406A2 (tr) * 2017-12-14 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Bi̇r i̇skelet kasi gevşeti̇ci̇si̇ ve bi̇r multi̇pl skleroz tedavi̇ edi̇ci̇ ajan i̇çeren kombi̇nasyonlar

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT505225A1 (de) * 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3398595A1 (fr) * 2012-08-03 2018-11-07 Fwp Ip Aps Polythérapie pour le traitement de la sclérose en plaques
WO2016073510A1 (fr) * 2014-11-04 2016-05-12 Adamas Pharmaceuticals, Inc. Méthodes d'administration de compositions d'amantadine
WO2018082814A1 (fr) * 2016-11-07 2018-05-11 Metriopharm Ag Utilisation de 5-amino-2,3-dihydro-1,4-phthalazinedione dans le traitement de la sclérose en plaques progressive chronique
TR201720406A2 (tr) * 2017-12-14 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Bi̇r i̇skelet kasi gevşeti̇ci̇si̇ ve bi̇r multi̇pl skleroz tedavi̇ edi̇ci̇ ajan i̇çeren kombi̇nasyonlar

Also Published As

Publication number Publication date
EP3902531A2 (fr) 2021-11-03
EP3902531A4 (fr) 2022-06-01
WO2020139238A2 (fr) 2020-07-02
TR201820976A2 (tr) 2020-07-21

Similar Documents

Publication Publication Date Title
EP4527467A3 (fr) Formulations pharmaceutiques
MX2020009857A (es) Conjugados de interleucina-2 (il-2).
ZA201902053B (en) Pharmaceutical composition
EP4467195A3 (fr) Agents thérapeutiques pour maladies neurodégénératives
HK1254343A1 (zh) 药物制剂
MY209101A (en) Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
WO2016125192A3 (fr) Procédé de préparation de dolutégravir
SG11202105540YA (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
WO2019194773A3 (fr) Combinaison contenant de la linagliptine et de la metformine
MX2020012989A (es) Agente terapeutico para la fibrosis.
WO2016196124A3 (fr) Promédicaments comprenant un lieur de pyroglutamate
EP4342461A3 (fr) Compositions pharmaceutiques et utilisations contre des troubles du stockage lysosomal
EP4467138A3 (fr) Agents thérapeutiques pour maladies neurodégénératives
EP4062938A4 (fr) Association médicamenteuse
WO2016006975A3 (fr) Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation
WO2016006974A3 (fr) Nouveaux dérivés triazolopyrimidinone ou triazolopyridinone et leur utilisation
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
SG11202104371XA (en) 1,3,4-oxadiazolone compound and pharmaceutical
WO2019203755A3 (fr) Forme pharmaceutique orale solide comprenant de la linagliptine
WO2020139238A3 (fr) Combinaisons pharmaceutiques comprenant du fingolimod et un spasmolytique
WO2020018053A3 (fr) Comprimé comprenant du dasatinib
WO2019245512A3 (fr) Combinaison comprenant du fingolimod et au moins un agent anti-épileptique
WO2019203748A3 (fr) Combinaison comprenant du raloxifène et au moins un agent antipsychotique
WO2019221684A3 (fr) Formulation de comprimé bicouche de fésotérodine
WO2019203746A3 (fr) Combinaison pharmaceutique comprenant du raloxifène et de l'aripiprazole

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019904739

Country of ref document: EP

Effective date: 20210728

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19904739

Country of ref document: EP

Kind code of ref document: A2